Identification of differentially expressed proteins in spontaneous thymic lymphomas from knockout mice with deletion of p53
Bent Honoré*1, Søren Buus2 and Mogens H Claësson2

Address: 1Institute of Medical Biochemistry, University of Aarhus, Ole Worms Allé, Bldg. 1170, DK-8000 Aarhus C, Denmark and 2Laboratory of Experimental Immunology, Faculty of Health Sciences, University of Copenhagen, Denmark

Email: Bent Honoré* - bh@biokemi.au.dk; Søren Buus - S.Buus@immi.ku.dk; Mogens H Claësson - CLAESSON@sund.ku.dk
* Corresponding author

Abstract

Background: Knockout mice with a deletion of p53 spontaneously develop thymic lymphomas. Two cell lines (SMS and SM7), established from two independent tumours, exhibited about fifty to seventy two-fold differentially expressed proteins compared to wild type thymocytes by two-dimensional gel electrophoresis (2D-PAGE).

Results: Protein spots excised from 2D-PAGE gels, were subjected to in-gel tryptic digestion and identified by liquid chromatography – tandem mass spectrometry. A total of 47 protein spots were identified. Immunological verification was performed for several of the differentially regulated proteins where suitable antibodies could be obtained. Functional annotation clustering revealed similarities as well as differences between the tumours. Twelve proteins that changed similarly in both tumours included up-regulation of rho GDP-dissociation inhibitor 2, proteasome subunit α type 3, transforming acidic coiled-coil containing protein 3, mitochondrial ornithine aminotransferase and epidermal fatty acid binding protein and down-regulation of adenylosuccinate synthetase, tubulin β-3 chain, a 25 kDa actin fragment, proteasome subunit β type 9, coflin-1 and glia maturation factor γ.

Conclusion: Some of the commonly differentially expressed proteins are also differentially expressed in other tumours and may be putative diagnostic and/or prognostic markers for lymphomas.

Background

The p53 protein is a ubiquitous transcription factor that is normally expressed at very low levels. In a majority of spontaneous virally- or chemically-transformed tumours, however, p53 protein expression increased. Single nucleotide mutations may result in transcription/translation of p53 protein without transcriptional nuclear activity. Consequently, mutated p53 protein accumulates in the cytoplasm where it is proteolytically fragmented. p53-derived peptides are presented by the MHC class I molecules to the immune system thereby functioning as potential tumour rejection epitopes [1].

Functionally, p53 protein halts proliferating cells in the G1 phase, where DNA repair occurs. In addition, p53 prevents mutations in newly synthesized DNA [2-6]. Individuals genetically deficient in p53, due to mutations or gene deletion, are more susceptible to the development of spontaneous tumours [5-7]. These data are consistent with the high frequency of tumours, in particular thymic...
lymphomas, observed in p53-/- mice from the 12th week of age [8].

Previously, we have analyzed transcript [8,9] and protein profiles [10] of wild type mice thymocytes and compared these with corresponding profiles of two independently established thymic lymphoma cell lines, SM5 and SM7. These cell lines spontaneously arose in p53 deleted knock-out mice. Based upon 2D-PAGE differential analysis, we identified significant changes in two protein spots (in p53 deleted cells) before tumour formation. The vast majority of changes, however, occurred after tumour formation. The SM5 cell line exhibited about seventy protein spot changes while SM7 displayed about fifty spot changes [10].

The aim of the present study was to establish the identity of these tumor-associated differentially expressed proteins. Using in-gel tryptic digestion and liquid chromatography – electrospray ionization – tandem mass spectrometry [11] we here report the identification of 47 of these protein spots.

Results
Differentially regulated proteins in thymic lymphomas
Figs. 1 and 2 display the gel localization of the proteins identified in the present study. Twelve protein spots, differentially expressed in both tumour cell lines (i.e. SM5 and SM7) are labelled using white numbering. Protein spots that were uniquely differentially expressed in SM5 or SM7 cells are labelled using black numbering. Protein identifications are listed in Tables 1, 2 and 3. Of the 47 identified spots, i.e. 472, 521, 707/730, 1216 and 1470 were ambiguously determined, since more than one protein were present in each spot. Thus, for these 5 spots it could not be unequivocally determined which of the proteins that were differentially expressed. Western blotting was used to verify several of the changes seen.

Commonly differentially regulated proteins
The commonly regulated proteins are given in Table 1. We identified up-regulation of rho GDP-dissociation inhibitor 2 (1236), proteasome subunit α type 3 (1062), transforming acidic coiled-coil containing protein 3 (131), mitochondrial ornithine aminotransferase (653) and epidermal fatty acid binding protein (1468).

![Two-dimensional gels of wt thymocytes (A) and of SM5 cells from a spontaneous derived tumour (B).](http://www.proteomesci.com/content/6/1/18)

**Figure 1**
Two-dimensional gels of wt thymocytes (A) and of SM5 cells from a spontaneous derived tumour (B). Identified proteins that change more than two-fold between wt thymocytes and the SM5 tumour cells are shown based upon previously detected differentially expressed protein spots [10]. Up-regulated proteins are shown with white arrows and down-regulated proteins with black arrows. Proteins that change similarly in the SM5 and SM7 tumour cells are indicated with white numbers. The identified proteins are listed in Tables 1 and 2. For alignment purposes the Canvas program was used for mutual adjustment of gels.
Among the down regulated proteins, we identified adenylosuccinate synthetase (622), tubulin β-3 chain (830/845), a 25 kDa actin fragment (1123), proteasome subunit β type 9 (1284), basic cofilin-1 variant (1357), acidic cofilin-1 variant (1363/1367) and glia maturation factor γ (1382).

**Uniquely differentially regulated proteins**

Tables 2 and 3 show the obtained peptides from uniquely regulated proteins. Unambiguously identified up-regulated proteins in tumour cells SM5 included: vinculin, serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A α isoform, prolyl 4-hydroxylase α-1 subunit, α enolase, ERC-55, eukaryotic translation initiation factor 3 subunit 4, eukaryotic translation initiation factor 1, triosephosphate isomerase, nucleoside diphosphate kinase B and in tumour cells SM7: 40 kDa peptidyl-prolyl cis-trans isomerase, acyl-protein thioesterase 1, and nudC domain-containing protein 2. Spots 298, 300, 302, 309 and 311 contained bovine albumin while spot 308 contained bovine α2HS-glycoprotein or fetuin. Spots 521, 472 and 1470 contained more than one protein.

Unambiguously identified down-regulated proteins in tumour cells SM5 included: poly(rC)-binding protein 1, proteasome inhibitor PI31 subunit, histone H4, ATP synthase α chain and in the SM7 tumour cell line: coronin-1A, adenosine deaminase, heterogeneous nuclear ribonucleoprotein A/B, 4-hydroxyphenyl puruvate dioxygenase, eukaryotic translation initiation factor 3 subunit 2, peroxiredoxin-2, ADP-ribosylation factor 1, ubiquitin-conjugating enzyme E2 N, actin-like protein 3 and transforming protein RhoA. Spots 707/730 and 1216 contained more than one protein.

**Immunological verification of differential regulation**

To independently confirm 2D-PAGE data, 1D Western Blot analysis was used to assess the differential expression of selected protein immunoreactive. Ideally, a single strong band on a Western blot reflects an antibody possessing high affinity with specific reaction against the antigen. The data obtained by Western Blot analysis is presented in Fig. 3.

Fig. 3A depicts Western blot analysis for three commonly regulated antigens: i.e. epidermal fatty acid binding protein (FABPE), proteasome subunit β type 9 (PSB9) and cofilin-1 (COFI1). Each produced strong bands in the cells where the proteins were present in high amounts. Furthermore the data are consistent with and confirm 2D-PAGE.
| Protein Identification | Peptide sequence | Charge | Mascot Score | Mr (Da) | pI | SM5 versus Wt | SM7 versus Wt |
|------------------------|------------------|--------|--------------|--------|----|-------------|-------------|
| Rho GDP-dissociation inhibitor 2/Ly-GDI | LNYKPPPQK (20–28) | 2 | 116 | 21,754 | 6.81 | Up | Up |
| Proteasome subunit α type 3 | SSGTGYDSLASTF SPDGR (1–19) (Acetyl N-term) AVENSTAI GIR (29–40) | 2 | 112 | 27,861 | 5.37 | Up | Up |
| Transforming acidic coiled-coil containing protein 3/ARNT-interacting protein TACC3_MOUSE | GLPAEPIDVLK (416–428) | 2 | 31* | 88,566 | 4.04 | Up | Up |
| Ornithine aminotransferase, mitochondrial OAT_MOUSE | AQAELALQASL R (582–594) TEQGPSSEYIFER (33–46) | 2 | 147 | 43,842 | 6.56 | Up | Up |
| Fatty acid binding protein, epidermal FABP_MOUSE | FDETTADGR (72–80) | 2 | 66 | 14,264 | 6.62 | Up | Up |
| Adenylosuccinate synthetase PURA2_MOUSE | VVDLLAQDADIV CR (46–59) | 2 | 140 | 45,185 | 6.95 | Up | Up |
| Tubulin β-3 chain TBBX_MOUSE | ALVDLEPGTMDS VR (63–77) | 2 | 36 | 36,980/36,445 | 6.26/6.25 | Up | Up |
| Actin (C-terminal) ACTX_MOUSE | DLTDYLMK (184–191) | 2 | 43 | 25,609 | 5.70 | Down | Down |
| Proteasome subunit β type 9/LMP-2d PSB9_MOUSE | VSAGTAVNR (40–49) | 2 | 129 | 19,837 | 4.42 | Down | Down |
| Cofilin-1 COF1_MOUSE | YALYDATYETK (81–91) | 2 | 65/65 | 17,159 | 7.16 | Down | Down |
| Cofilin-1 COF1_MOUSE | YALYDATYETK (81–91) | 2 | 20** | 17,199 | 6.38 | Down | Down |
| Glia maturation factor γ GMFG_MOUSE | LVQTAELTK (111–119) | 2 | 117/75 | 16,626 | 5.56 | Down | Down |
data. That is, that FABPE is more than 2-fold up-regulated in both of the tumour cells and that PSB9 and COF1 are both more than 2-fold down-regulated in tumour cells.

Fig. 3B and 3C depict Western blot data that verifies the differential regulation of selected uniquely regulated proteins. That is, eukaryotic translation initiation factor 3 subunit 4 (IF34) and triosephosphate isomerase (TPIS) were found to be more than 2-fold up-regulated in the SM5 cell line but in fact also in the SM7 cell line. Similarly, down-regulation in tumour cells SM7 was confirmed in case of the proteins coronin-1A (COR1A, 10-fold), heterogeneous nuclear ribonucleoprotein A/B (ROAA, 9-fold), peroxiredoxin-2 (PRDX2, 1.5-fold), ubiquitin-conjugating enzyme E2 N (UBE2N, >10-fold) and actin-like protein 3 (ARP3, 3.1-fold). All of these proteins were also down-regulated in the tumour SM5.

Table 1: Differentially regulated proteins commonly found in two different tumours, SM5 and SM7 (Continued)

| Peptide Sequence | Up/Down | SM5 Cell Line | SM7 Cell Line |
|------------------|---------|---------------|---------------|
| TTDDLTEWTK       | Up      | 2             | 3             |
| (125–135)        |         |               |               |

The significance level for the peptides given were p < 0.05 when searching in the total database except the protein indicated with (*) that was significant when searching in the mouse part of the database and the peptide given with (**) that was not significant. The non-significant peptide (1363/1367) was included because of the similarity to the significant peptide 1357.

*a Up, protein that is up-regulated in SM5 cells versus wt. Down, protein that is down-regulated in SM5 cells versus wt.

b Up, protein that is up-regulated in SM7 cells versus wt. Down, protein that is down-regulated in SM7 cells versus wt.

c X is 2A, 2B, 3 or 5

d X is A, B, C, G, H or S

With respect to the five spots containing more than one protein we tried antibodies against UV excision repair protein RAD23 homolog B (472), galectin-7 (1470) and Ras related protein Rab-11A (spot 1216). Unfortunately, the quality of the results was insufficient for firm conclusions.

Discussion

Previously, we have detected differentially-expressed proteins in spontaneously formed tumours in p53 knockout mice [10]. Changes in the expression of two of the proteins identified preceded tumour formation. In the vast majority, however, changes in expression coincided with or paralleled tumour formation, with about seventy protein spots changing in the SM5 cell line while about fifty spot changes were found in the SM7 cell line. The aim of this study was to further characterise and identify, tumour-associated changes in protein expression.

A subset of the proteins were commonly regulated, changing at least two-fold by 2D-PAGE in both tumours while a number of proteins, originally detected in one of the tumours also could be found to be differentially regulated in the other tumour as detected by immunodetection. Such differentially expressed proteins may represent proteins that are of general importance in order to understand the transformation process initiated by the deletion of p53. Furthermore, some of them might be suitable as diagnostic or prognostic markers for lymphomas or other tumours that include deletion of p53. Several genes responsive to elevated levels of p53 have been identified [16-18]. In the p53 deleted cells we did not detect differential regulation of direct downstream targets of p53 within the major pathways including cell cycle arrest, DNA repair, apoptosis, angiogenesis or cellular stress response. We did observe down regulation of a C-terminal actin fragment in both cell lines (spot 1123). α-actin has been reported to be a transcriptional target of p53 [19] and down-regulation could be due to a decreased expres-
Table 2: Differentially regulated proteins in the SM5 tumour

| Protein Identification | Sequence | Charge | Mascot Score | Mr    | pI       | SM5 versus wt |
|------------------------|----------|--------|--------------|-------|----------|---------------|
| Vinculin VINC_MOUSE    | SLGELAALS (433–443) | 2      | 29         | 101.649 | 6.64     | Up            |
| Albumin ALBU_BOVIN     | LVNELTEFAK (66–75) | 2      | 569/623/164/505 | 64.8−65.6 (kDa) | 5.92–6.37 | Up            |
| α-2HS-glycoprotein FETUA_BOVIN | HTLNQIDSVK (58–67) | 2      | 519         | 63.2 (kDa) | 3.58     | Up            |
| Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A α isoform 2AAA_MOUSE | LAGGDWFTSR (134–143) | 2 138/70 | 61,309 | 4.97 Up |
Table 2: Differentially regulated proteins in the SM5 tumour (Continued)

| 385 | Prolyl 4-hydroxylase α-1 subunit P4HA1_MOUSE | MAGDPVANVR (527–536) | 2 | 61/140 | 59,705 | 6.06 | Up |
| 521 | Ig α-1 chain C region IGHA1_HUMAN/ Lysozyme C LYSC_HUMAN/Deleted in malignant brain tumours 1 protein DMBT1_HUMAN | LTQDQVDVYK (566–575) | 2 | 61/140 | 59,705 | 6.06 | Up |
| 521 | | LQDTYNLDNTNI SK (137–150) | 2 | 61/140 | 59,705 | 6.06 | Up |
| 521 | | RPCTLSELE (526–534) | 2 | 61/140 | 59,705 | 6.06 | Up |
| 584 | α-enolase ENOA_Mouse | DASGVFTTWTPS SGK (154–168) | 2 | 181 | 50,620 | 6.15 | Up |
| 592 | α-enolase ENOA_Mouse | WLQGSQELPR (264–273) | 2 | 87 |
| 592 | | QEPSQTTTFAV TSILR (283–299)/ STDYGIFQINSR (69–80)/ FGQGSGPVLDD VR (73–86) | 2 | 77 |
| 641 | ERC-55 RCN2_MOUSE | GDPCQESHGIYGE ALELR (32–49) | 2 | 179 | 46,971 | 7.03 | Up |
| 650 | Eukaryotic translation initiation factor 3 subunit 4 IF34_MOUSE | VNLSEDTR (243–251) | 2 | 53 | 44,126 | 5.83 | Up |
| 650 | | VTNLSEDTR (243–251) | 2 | 53 | 44,126 | 5.83 | Up |
| 814 | Eukaryotic translation initiation factor 2 subunit 1 IF2A_MOUSE | DASGVFTTWTPS SGK (154–168) | 2 | 181 | 50,620 | 6.15 | Up |
| 814 | | WLQGSQELPR (264–273) | 2 | 87 |
| 814 | | QEPSQTTTFAV TSILR (283–299)/ STDYGIFQINSR (69–80)/ FGQGSGPVLDD VR (73–86) | 2 | 77 |
| 814 | | GDPCQESHGIYGE ALELR (32–49) | 2 | 179 | 46,971 | 7.03 | Up |
| 1134 | Triosephosphate isomerase TPIS_MOUSE | GDPCQESHGIYGE ALELR (32–49) | 2 | 179 | 46,971 | 7.03 | Up |
| 1384 | Nucleoside diphosphate kinase B NDKB_MOUSE | VTNLSEDTR (243–251) | 2 | 53 | 44,126 | 5.83 | Up |
| 472 | UV excision repair protein RAD23 homolog B RD23B_MOUSE/ Endoplasm ENPL_MOUSE | VTNLSEDTR (243–251) | 2 | 53 | 44,126 | 5.83 | Up |

*Note: The table continues with additional entries for proteins and their corresponding changes in abundance between the SM5 tumour and control samples.*
Table 2: Differentially regulated proteins in the SM5 tumour (Continued)

| ID   | Protein Name                      | Protein Accession | Start | End   | p Value | Log2 Fold Change | Regulation |
|------|-----------------------------------|-------------------|-------|-------|---------|-----------------|------------|
| 707/730 | Actin ACTB_MOUSE/UBA/UBX 33.3 kDa protein U33K_MOUSE | AGFAGDDAPR (1–10) | 2     | 156   |         | 41.158/40.562   | 5.19/5.23 Down |
|       |                                   | GYSFTTTAER (179–188) | 2     |       |         |                 |            |
|       |                                   | SYELPDQVITVG NER (218–233)/LPDGTSLTQTFR (220–231) | 2     | 74    |         |                 |            |
| 761   | Poly(rC)-binding protein I PCBPI_MOUSE | INISEGNCPER (47–57) | 2     | 110   |         | 39.587          | 7.46 Down  |
|       |                                   | IANPVEGSSGR (315–325) | 2     |       |         |                 |            |
| 972   | Proteasome inhibitor P31 subunit PSMF1_MOUSE | VLIDPSSGLPNR (220–231) | 2     | 43    |         | 31.039          | 4.68 Down  |
|       | Histone H4 H4_MOUSE                | ISGLYETETR (46–55) | 2     | 32a   |         | 30.490          | 7.22 Down  |
| 1031  | ATP synthase α chain, mitochondrial ATPA_MOUSE | VLSIDGDIAR (74–83) | 2     | 86    |         | 29.286          | 9.32 Down  |
|       |                                   | VVDALGNAIDGK (150–161) | 2     |       |         |                 |            |

The significance level for the peptides given were p < 0.05 when searching in the total database except the peptides indicated with (*) that were significant when searching in the mouse part of the database.

a Up, protein that is up-regulated in SM5 cells versus wt. Down, protein that is down-regulated in SM5 cells versus wt.
b The peptide was not given as bold in the search, but was similar to a bold peptide in various other species except that L was exchanged with I.

sion of the actin gene. The observation might also be explained by a decrease in the cleavage of the actin protein.

**Functional annotation clustering of differentially regulated proteins**

Each of the identified proteins may be functionally classified based on the Gene Ontology annotation system [20]. This system is a structured, organized vocabulary that systematically describes each protein with respect to cellular component, biological process and molecular function. By using the DAVID Bioinformatics Resource [21] we performed a functional annotation clustering of the proteins involved in the transformation. With the highest classification stringency, we found seven clusters for SM5 and eleven clusters for SM7 as shown in Tables 4 and 5. The clusters are listed with the most enriched at top. For example, the 3 proteins PURA2, NKB and ATPA of the 24 proteins analyzed with the cell line SM5 belong to the cluster purine nucleotide biosynthetic process. The p value at 0.0039 indicates that this function is significantly over represented among the 24 proteins analyzed. Similarly, proteins involved in cellular process, glucose metabolic process, translation factor activity (nucleic acid binding) and the actin cytoskeleton were all significant. Some of the proteins belong to more than one category since they possess multiple functions. The SM7 cell line was in some respects similar to SM5 but in other respects different since functions that were over represented by the transformation included GTP binding, cytoskeleton, cellular process, ubiquitin-dependent protein catabolic process, intracellular transport and GTPase activity. The partly different functions of the two cells may partly explain the different physiology of the two cell lines where SM7 is 3–5 times more tumourigenic compared with SM5 [10].

**Differentially regulated cancer related proteins**

Oncogenesis is not a term within the Gene Ontology classification. However, some of the commonly regulated proteins are known from other studies also to be involved in carcinogenesis and will be briefly described.

**Rho GDP-dissociation inhibitor 2 (1236)**

Rho GDP-dissociation inhibitor 2 is preferentially expressed in lymphocytes [22] and found to be up-regulated in the two tumour cells analyzed. Recently, the protein was also found to be up-regulated in oral squamous cell carcinoma whereas the mRNA level was only very slightly up-regulated [23]. The Rho GDP-dissociation inhibitors play a role in the modulation of the activity of the Rho proteins. Overexpression leads to rounding up of cells and loss of stress fibers and focal contact sides [24].

**Transforming acidic coiled-coil containing protein 3 (TACC3) (131)**

TACC3 was found to be up-regulated in both tumour cell lines. The transcript has been previously found to be strongly present in testis, at low level in human thymus and very low levels in a number of tissues of the immune system while several cancer cell lines express up-regulated levels of the transcript [25]. Recently, Jung et al. have found TACC3 protein expression to be a prognostic marker of non-small cell lung carcinoma where 14.8% of
| Protein Identification | Sequence | Charge | Mascot score | Mr | pl | SM7 versus wt |
|------------------------|----------|--------|--------------|----|----|----------------|
| 777 40 kDa peptidyl-prolyl cis-trans isomerase PPID_MOUSE | TLENVEVGKEPKAK (160–173) ILLISIDLKL (218–226) EYQALADLK (321–330) | 2 | 66 | 39,459 | 5.23 | Up |
| 1124 Acyl-protein thioesterase 1 LYPAI-MOUSE | ASFGQPINSANR (150–162) | 2 | 54 | 25,565 | 5.88 | Up |
| 1400 NudC domain-containing protein 2 NUDC2_MOUSE | AQDIQCGLQSR (40–50) | 2 | 57 | 16,128 | 4.76 | Up |
| 1470 40S ribosomal protein S12 RS12_MOUSE/Galectin-7LEG7_MOUSE | AEEGIAAGGMDVNTALQEV LK (1–22) (Acetyl N-term) LGEWVGCLK (84–92)/LTDSLEVFTNK (54–64) VSQTTWDSGFACVPNK (30–45) | 2 | 125 | 14,314 | 7.83 | Up |
| 467 Coronin-1A COR1A_MOUSE | VSQTTWDSGFACVPNK (30–45) DGAIICTSCR (187–196) ILTTGFSR (234–241) QVALWDTK (246–253) DGAIIPLILSK (384–393) ATPEPSGTSSPDYTR (417–432) | 2 | NS | 54,369 | 6.95 | Down |
| 460 Coronin-1A COR1A_MOUSE | VSQTTWDSGFACVPNK (30–45) DGAIIPLILSK (384–393) | 2 | 185 | 54,369 | 6.74 | Down |
| 453 Coronin-1A COR1A_MOUSE | VSQTTWDSGFACVPNK (30–45) DGAIIPLILSK (384–393) | 2 | 123 | 54,503 | 6.59 | Down |
| 727 Heterogeneous nuclear ribonucleoprotein A/B ROAA_MOUSE | IFVGGLNPEATEEK (161–174) | 2 | 113 | 40,104 | 7.11 | Down |
| 853 4-hydroxyphenyl puruvate dioxygenase HPPD_MOUSE | TEDIITAIR (270–278) | 2 | 28* | 36,980 | 6.66 | Down |
| 835 Eukaryotic translation initiation factor 3 subunit 2 IF32_MOUSE | SYSSGGEDGVR (299–310) | 2 | 56/51 | 36,622 | 5.89 | Down |
| 1216 Ras-related protein Rab-11B RB11B_MOUSE/ATP-dependent RNA helicase DDX39 DDX39_MOUSE | GAVGALLVYDIK (82–94) | 2 | NS | 22,463 | 5.87 | Down |
| 1243 Peroxiredoxin-2 PRDX2_MOUSE | NITLIEYR (166–173)/ILVATNLFG (338–348) GLFIDAK (128–135) QTVNLPVGR (140–150) ILMVGLDAAGK (19–29) LLAEVPGIK (15–24) | 2 | 90 | 21,457 | 4.76 | Down |
| 1364 ADP-ribosylation factor 1 ARFX_MOUSE | LLLVQNLG (120–126) | 2 | 106 | 21,457 | 4.76 | Down |
| 1430 Ubiquitin-conjugating enzyme E2 N UBE2N_MOUSE | TNEAQAYETAR (131–141) YSYVCPDLVK (231–240) NIVLSGGSTMFR (318–329) LSEELSGGR (349–357) DYEAEFPSICR (399–409) | 2 | NS | 17,059 | 6.80 | Down |
| 599 Actin-like protein 3 ARP3_MOUSE | EVYQQQYGYSGGR (238–250) | 2 | 113 | 40,104 | 7.11 | Down |
Table 3: Differentially regulated proteins in the SM7 tumour (Continued)

| ID  | Peptide                        | SM7/WT  | Change |
|-----|--------------------------------|---------|--------|
| T184| Transforming protein RhoA       | LVIVGDGACGK (8–18) | 2 | 79 | 23,410 | 6.82 | Down |
|     |                                | IGAFGMECSAK (151–162) | 2 | |

The significance level for the peptides given were p < 0.05 when searching in the total database except the peptide indicated with (‘*’ that was significant when searching in the mouse part of the database and the peptide given with (‘**’ that was not significant. The non-significant peptide (727) was included because of the similarity to the significant peptide 740.

* Up, protein that is up-regulated in SM7 cells versus wt. Down, protein that is down-regulated in SM7 cells versus wt.

b X is 1, 2, 3, 4 or 5.

The tumours expressed high levels [26]. The authors also found TACC3 expression to be correlated with p53 expression and that patients with high expression of both proteins had significantly poorer prognosis than patients with low-level expression of both [26].

Ornithine aminotransferase (653)

Ornithine aminotransferase (OAT) was found to be up-regulated in both tumour cell lines. Previously, it has been found by subtractive hybridisation that the transcript of OAT is up-regulated in hepatocellular carcinomas [27].

Figure 3

Western blots of wt thymocytes and thymocytes from two spontaneously arising tumours, SM5 and SM7. Equal amounts of protein were added to the lanes used for analysis of one antibody, either 5, 10 or 30 mg per lane. The bands were scanned and quantitated using the Quantity One program. The measured changes are indicated below the blot with wild type arbitrarily set to 1.0. Proteins that, from 2D-PAGE analysis, were found to change at least 2-fold are given in (A) for the commonly regulated and in (B) and (C) for the individually changed in SM5 and SM7, respectively.
### Table 4: Functional annotation clustering of proteins involved in the transformation of tumour cell line SM5

| Functional annotation clustering | Function                                                                 | Proteins involved | P value |
|---------------------------------|--------------------------------------------------------------------------|-------------------|---------|
| Purine nucleotide biosynthetic process | The chemical reactions and pathways resulting in the formation of a purine nucleotide, a compound consisting of a purine base linked to a deoxyribose or ribose sugar esterified with a phosphate moiety at either the 3' or 5'-hydroxyl group of its glucose moiety. | PURA2, NKDB, ATPA, H4 | 0.0039  |
| Cellular process | Processes that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. | PSB9, TBB3, VINC, IF34, PURA2, ENOA, IF2A, ATPA, P4HA1, FABPE, COFI, TPIS, TACC3, PSA3, NDKB, ACTB, PCBP1, OAT, TPIS | 0.047  |
| Glucose metabolic process | The chemical reactions and pathways involving glucose, the aldohexose gluco-hexose. D-glucose is dextrorotatory and is sometimes known as dextrose; it is an important source of energy for living organisms and is found free as well as combined in homo- and hetero-oligosaccharides. | ENOA, FABPE, IF34 | 0.006  |
| Translation factor activity, nucleic acid binding | Functions during translation by binding nucleic acids during polypeptide synthesis at the ribosome. | IF2A, PCBP1, COFI | 0.011  |
| Actin cytoskeleton | The part of the cytoskeleton (the internal framework of a cell) composed of actin and associated proteins. Includes actin cytoskeleton-associated complexes. | VINC, ACTB, NDKB, ATPA, ACTB, COFI | 0.022  |
| ATP binding | Interacting selectively with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. | VINC, ACTB, NDKB, ATPA, ACTB, COFI | 0.48  |
| Regulation of cellular process | Any process that modulates the frequency, rate or extent of cellular processes, those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. | VINC, TACC3, IF2A | 0.76  |

*For each cluster is listed the GO term possessing the highest enrichment score using the DAVID bioinformatics Resource [21]. In some cases this GO term was obsolete in which case the nearest well defined term was listed.*
Table 5: Functional annotation clustering of proteins involved in the transformation of tumour cell line SM7

| Functional annotation clustering | Function | Proteins involved | P value |
|----------------------------------|----------|-------------------|---------|
| GTP binding                      | Interacting selectively with GTP, guanosine triphosphate. | TBB3  
ARF1  
PURA2  
RHOA  
COF1 | 0.0073 |
| Cytoskeleton                     | Any of the various filamentous elements that form the internal framework of cells, and typically remain after treatment of the cells with mild detergent to remove membrane constituents and soluble components of the cytoplasm. The term embraces intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles. | TBB3  
TACC3  
ARP3  
RHOA  
ACTB  
PSEA | 0.0012 |
| Cellular process                 | Processes that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. | TBB3  
PUR4  
ROAA  
PRDX2  
ADA  
LYPA1  
FABP2  
IF32  
COF1  
ARFI  
TACC3  
HPPD  
PSA3  
PPIP  
ACTB  
UBE2N  
OAT  
PSEA | 0.047 |
| Ubiquitin-dependent protein catabolic process | The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of a ubiquitin moiety, or multiple ubiquitin moieties, to the protein. | PSA3  
UBE2N  
PSEA | 0.010 |
| Intracellular transport          | The directed movement of substances within a cell. | TBB3  
ARFI  
TACC3  
RHOA | 0.042 |
| GTPase activity                 | Catalysis of the reaction: GTP + H2O → GDP + phosphate. | TBB3  
ARFI  
TACC3  
RHOA  
PSEA | 0.010 |
| Cellular protein metabolic process | The chemical reactions and pathways involving a specific protein, rather than of proteins in general, occurring at the level of an individual cell. Includes protein modification. | COF1  
TBB3  
PSA3  
PPIP | 0.098 |
Epidermal fatty acid binding protein (1468)

E-FABP is a fatty acid binding protein that was originally found to be up-regulated in psoriatic skin [28]. Recently, it was found that E-FABP is up-regulated in head and neck squamous cell carcinomas and a number of carcinoma cell lines [29]. In addition, it was found that EpCAM, a tumour associated antigen, up-regulates E-FABP and furthermore that EpCAM is positively correlated with the grade of dysplasia being a negative prognostic factor for breast cancer patients [29].

Proteasome subunit type 9 (LMP2)

The proteasome is a complex structure localized in the cytosol and composed of several different subunits. Some of the subunits are constitutively expressed while others, including LMP2, belong to the facultative subunits that may exchange with the constitutively expressed subunits as a result of immune stress [30]. Proteasome subunit β type 9 was down-regulated in the tumour cells analyzed here. It has previously been found that LMP2 generally is down-regulated in several types of tumours such as laryngeal squamous cell carcinoma [31], head and neck squamous cell carcinoma [32], renal cell carcinoma [33], as well as in a number of tumour cell lines including small-cell lung carcinoma, hepatocellular carcinoma, colon adenocarcinoma and basophilic leukemia [34].

Plasma derived proteins

In SM5 cells we identified two proteins that were markedly present and clearly originated from bovine plasma, fetuin (308) and albumin (298, 300, 302, 309 and 311). Both proteins were detected from SM5 cells but were only vaguely seen in SM7 cells. The likely differences between the isoforms of BSA are various types of modifications that may occur, e.g. following oxidation [35]. These modifications include glycosylations at a number of Lys residues. Since the cells were treated similarly, it is unlikely that the presence of them in one of the cell lines is due to contamination obtained during the preparation of the cells. Endothelial cells have previously been shown to take up fetuin [36]. Recently, it was shown that fibroblasts are also able to perform this internalization and that the internalization is down-regulated by hypoxia [37]. The present study indicates that especially transformed thy-mocytes (SM5) may have gained the ability to perform this internalisation. We, however, cannot exclude that the proteins also could adhere to the surface of the cells rather than being internalized.

Comparison with previous observed changes in mRNA in SM7

Using one of the early mouse oncogene arrays, Atlas mouse array I (Clontech) encompassing 588 oncogenes, we have previously identified several differentially regulated transcripts in the two tumour cell lines [8,9]. Only a few overlaps were found between the identified set of pro-

| Table 5: Functional annotation clustering of proteins involved in the transformation of tumour cell line SM7 (Continued) |
|---|---|---|
| Intracellular protein transport | The directed movement of proteins in a cell, including the movement of proteins between specific compartments or structures within a cell, such as organelles of a eukaryotic cell. | IF32  
UBE2N  
ARF1  
0.094 |
| Negative regulation of cellular process | Any process that stops, prevents or reduces the frequency, rate or extent of cellular processes, those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. | TACC3  
RHOA  
TACC3  
0.19 |
| Regulation of cellular process | Any process that modulates the frequency, rate or extent of cellular processes, those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. | RHOA  
PRDX2  
COFI  
0.53 |
| Ion binding | Interacting selectively with ions, charged atoms or groups of atoms. | TACC3  
RHOA  
ROAA  
PRDX2  
PURAA  
HPDD  
ADA  
0.93 |

*For each cluster is listed the GO term possessing the highest enrichment score using the DAVID bioinformatics Resource [21]. In some cases this GO term was obsolete in which case the nearest well defined term was listed.
Proteins differentially expressed here and the previously identified differentially regulated transcripts. These included nucleoside diphosphate kinase B, UV excision repair protein RAD23 homolog B, and ubiquitin regulating enzyme E2.

Conclusion
We detected and identified several proteins, that were differentially regulated as a result of transformation following deletion of the p53 gene. Immunological verification of differential regulation was performed in 8 of 11 cases. Among the two cell types SM5 and SM7 that differed in their carcinogenic potential, we also found differences in the functional annotation clustering. A major part of the commonly regulated set of proteins have previously been found to be related to several other types of cancers indicating that they may play a role in the transformation process. Studies will be performed to investigate their putative role as diagnostic or prognostic biomarkers in human lymphomas. Biopsies could be histochemically analyzed using antibodies against the differentially expressed proteins in order to diagnostically and/or prognostically classify lymphomas. Putative up-regulated proteins might further be analyzed for their presence in the blood to be used as diagnostic and/prognostic biomarkers.

Methods
Analysis of two-dimensional gels
The performance and analysis of two-dimensional gels have been described in detail previously [10]. Briefly, silver stained gels were scanned in the transmissive mode on a GS-710 Imaging Densitometer (Bio-Rad) using Quantity One. The 16-bit gray scale TIFF files were imported into Melanie II. Initially, protein spots were automatically defined and quantified. Spot intensities were expressed as relative volumes in percentages (%VOL) by integrating the optical density of each pixel in the spot area (VOL) and dividing with the sum of volumes of all spots detected. About 10–12 of the spots were used as landmarks. One of the gels was selected as reference gel and used to align and match the other gels. The quality of the match was critically evaluated and necessary editions and corrections done manually. Comparisons were performed between two groups of gels by selecting spots that differed more than two-fold between the groups. These data were exported to Excel for further statistical analysis using Student's t-test as previously described [10].

Identification of proteins by liquid chromatography-tandem mass spectrometry (LC-MS/MS)
Protein identification by LC-MS/MS was performed as previously described [38]. Briefly, previously run gels containing protein spots selected for identification were re-hydrated in water. The cellophane sheets were peeled off so the protein spots could be excised from the gels. Proteins were in-gel digested with trypsin. Gel pieces were first dehydrated in acetonitrile, then dried and proteins reduced for 1 h at 56°C in 10 mM dithiothreitol (DTT) and 100 mM NH4HCO3. The solution was exchanged with 55 mM iodoacetamide in 100 mM NH4HCO3 for 45 min. Then it was washed in 100 mM NH4HCO3, dehydrated in acetonitrile, rehydrated in 100 mM NH4HCO3, dehydrated in acetonitrile, dried and swelled in digestion buffer (50 mM NH4HCO3, 5 mM CaCl2 and 12.5 ng/μl trypsin Gold (mass spectrometry grade; Promega, Madison, WI, USA). Digestion was performed overnight at 37°C and the peptides were extracted by 1 change of 20 mM NH4HCO3 and 3 changes of 5% formic acid in 50% acetonitrile. The sample was finally dried and the peptides resuspended in 12 μl of buffer A (water/acetonitrile/formic acid, 97.7/2/0.3, V/V/V). The peptides were separated on an inert nano LC system composed of a FAMOS micro autosampler, a Switchos micro column switching module and an Ultimate micro pump from LC Packings (San Francisco, CA) before MS analysis. Of the in-gel digested samples 5 μl was preconcentrated and desalted on a 300 μm inner diameter × 5 mm Nano Precolumn (LC Packings) packed with 5 μm C18 PepMap100 material. A 75 μm inner diameter × 15 cm Nano column packed with 3 μm C18 PepMap100 material was used to separate the peptides. Elution from the column was made with a gradient by mixing decreasing volumes of buffer A with increasing volumes of buffer B (water/acetonitrile/formic acid, 9.7/90/0.3, V/V/V). The peptides were eluted into the nano electrospray ion source of the quadrupole time-of-flight Q-TOF Ultima mass spectrometer (Micromass, Manchester, UK). MS survey scans were acquired using MassLynx 4 SP4 (Waters) at a rate of 1 per second from m/z 400–2000. The instrument was operated in a data-dependent MS to MS/MS switching mode. Doubly, triply and quadruply charged peptide ions detected in MS survey scans triggered a switch to MS/MS for obtaining peptide fragmentation spectra with an interval of m/z values 50–2000. Raw data were processed using ProteinLynx GlobalServer 2.1 (Waters). Processing parameters were as follows: Background Subtract: Normal, Background Threshold: 35%, Background Polynomial: 5, Smoothing Type: Savitzky-Golay, Smoothing Iterations: 2, Smoothing Window: 2 channels, Deisotoping Type: Normal, Deisotoping Threshold: 1%. The processed data were used to search the total part and the mouse fraction of the Swiss-Prot database (releases 49.7, 54.0 and 54.4) using the on-line version of the Mascot MS/MS Ion Search facility (Matrix Science, Ltd., http://www.matrixscience.com) [39]. Searching was performed with doubly and triply charged ions with 2 missed cleavages, a peptide tolerance of 20, 50 or 100 ppm, one variable modification either Carbamidomethyl-C or N-terminal acetyl and an MS/MS tolerance of 0.05 or 0.08
Da. Contaminating peptides, including keratins and trypsin were disregarded. At least one ‘bold red’ peptide was required in the search. Peptides for proteins with scores giving a less than 5% probability that the observed match was a random event are reported.

Western blotting
Normal C57BL/6 mice (wt) were purchased from Bom-holtegaard, Ry, Denmark. The mice were kept under conventional conditions at the animal facility at the Panum Institute. The thymus was pressed through a metal net and single cell suspensions were recovered on a foetal calf serum gradient allowing clumps and debris to settle. By haemocytometer examination more than 99% of the cells are lymphoid. Thymocytes were prepared from three mice and pooled. They were then washed extensively in PBS and lyophilized. C57BL/6-Trp53tm1Tyj mice deficient for the p53 gene were purchased from the Jackson Laboratory, USA. Two spontaneously developing thymic lymphomas, SM5 and SM7, were explanted, in vitro cultured, and established as cell lines growing in RPMI-1640 culture medium supplemented with 10% fetal calf serum and established as cell lines growing in RPMI-1640 culture medium supplemented with 10% fetal calf serum and 50 μM 2-mercaptoethanol. Cells were washed extensively in PBS, harvested with a rubber police man and lyophilized. Protein concentration was determined using Densitometer from Bio-Rad and the intensities of the bands were evaluated using the Quantity One software package. Each band was thereby visualized on film (Kodak), scanned with a GS-710 Imaging densitometer from Bio-Rad using the Quantity One software package. Each band was thereby visualized on film (Kodak), scanned with a GS-710 Imaging densitometer from Bio-Rad using the Quantity One software package.

Several antibodies were obtained from commercial suppliers. The following rabbit antibodies were used: anti-cofilin (Abcam), dilution 1:10,000 (9 μg/ml); anti-ubiquitin conjugating enzyme E2 N (Calbiochem), dilution 1:10 (50 μg/ml); anti-proteasome 20S LMP2 (Abcam), dilution 1:100 (1 μg/ml); anti-peroxiredoxin 2 (Abcam), dilution 1:2,000 (0.5 μg/ml); anti-transforming acidic coiled coil containing protein 3 (Biolegend), dilution 1:5; anti-NM23-H1/H2 (Alexis) dilution 1:100 (10 μg/ml); anti-RAD23B (Abgent), dilution 1:10 (25 μg/ml); anti-cyclophilin 40 PPID (Abcam), dilution 1:10; anti-galecin 7 (Abcam), dilution 1:30 (33 μg/ml); anti-adenosine deaminase (ADA) (Nordic Biosite), dilution 1:20; anti-Rab11a (Nordic Biosite), dilution 1:60 (2 μg/ml); anti-Ly-CDI (Santa Cruz Biotechnology, INC.), dilution 1:50 (4 μg/ml); anti-serine/threonine protein phosphatase 2a/a (Sigma), dilution 1:10 (10 μg/ml). The following mouse antibodies were used: anti-ADP ribosylation factor (Abcam), dilution 1:50; anti-proteasome 20S α 3 (Abcam), dilution 1:25; anti-Actin like protein 3 (Arp3) (BD Biosciences Pharmingen), dilution 1:100 (2.5 μg/ml); anti-hnRNP-A2/B1 (ImmuQuest, Ltd.) dilution 1:500 (2 μg/ml); anti-vinculin (Abcam), dilution 1:10 (1 mg/ml); anti-Rho GDP-dissociation inhibitor 2 (Rho-GDI2) (Alexis) dilution 1:10 (50 μg/ml). The following goat antibodies were used: anti-coronin 1 (Everest Biotech), dilution 1:100 (5 μg/ml); anti-FABP5 (R & D Systems), dilution 1:10 (20 μg/ml); anti-triosephosphate isomerase (TP11) (Everest Biotech, Ltd.), dilution 1:1,000 (0.5 μg/ml); anti-ef3β (Santa Cruz Biotechnology, Inc.), dilution 1:5 (40 μg/ml). The following chicken antibody was used: anti-eukaryotic translation initiation factor 3, subunit 4 β, 44 kDa (EIF3S4), (GenWay Biotech, Inc.), dilution 1:1,000 (1 μg/ml). Secondary HRP conjugated antibodies were purchased from DAKO (Denmark): anti-rabbit PO217, dilution 1:5,000 (0.26 μg/ml); anti-mouse PO260, dilution 1:5,000 (0.26 μg/ml); anti-goat, PO449, dilution 1:5,000 (0.1 μg/ml) and from Abcam (UK) anti-chicken (ab16349), dilution 1:2,500. Imaging Kodak films were scanned in the transmissive mode on a GS-710 Calibrated Imaging Densitometer from Bio-Rad using the Quantity One software package. Each band was thereby designated a value proportional to the protein concentration in the band. The quality of the antibody reactions was evaluated on the basis of the Western blots where a single strong band indicates a high-affinity specific antibody. Several antibodies were found to give Western blots of insufficient quality in our system either because reactions were too weak or because of the presence of several bands indicating that the antibody possesses low-affinity and/or unspecific reactivity in the given system.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
BH conceived the study, carried out the mass spectrometry determinations and immunoblotting analyses, interpreted the data and drafted the manuscript, SB participated in interpretation of data and revised the manuscript critically, MHC conceived the study, performed the cell
preparations and revised the manuscript critically. All authors read and approved the final manuscript.

Acknowledgements
We thank Professor Gregory E. Rice, University of Melbourne, Australia for discussions and editorial assistance. We thank Inge Kjærgaard for expert technical assistance. This work was supported by grants from the Danish Medical Research Council, the John and Birthe Meyer Foundation, the Novo Nordisk Foundation and Aarhus University Research Foundation.

References
1. Offringa R, Vierboom MP, Burg SH van der, Erdile L, Melief CJ: p53: a potential target antigen for immunotherapy of cancer. *Ann N Y Acad Sci* 2000, 910:223-233. discussion 233–226.
2. Eliyahu D, Raza A, Gruss P, Givol D, Oren M: Participation of p53 cellular tumor antigen in the regulation of normal embryonic cells. *Nature* 1984, 312:646-649.
3. Matlashewski G, Banks L, Pim D, Crawford L: Analysis of human p53 proteins and mRNA levels in normal and transformed cells. *Eur J Biochem* 1986, 154:665-672.
4. lane DP, Benchimon S: p53: oncogene or anti-oncogene? *Genes Dev* 1990, 4:1-8.
5. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. *Science* 1991, 253:49-53.
6. Caron de Fromentel C, Soussi T: TP53 tumor suppressor gene: a model for investigating human mutagenesis. *Genes Chromosom Cancer* 1992, 2:1-15.
7. Wang XW: Role of p53 and apoptosis in carcinogenesis. *Anti-cancer Res* 1999, 19:4759-4771.
8. Mathiassen S, Lau, Knolle SL, Ruhlwald M, Claes, Hansen, Buus S: Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. *Eur J Immunol* 2001, 31:1239-1246.
9. Andersen ML, Ruhlwald M, Thomsen M, Pedersen AE, Mathiassen S, Buus S, Claessen MH: Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes. *J Immunol* 2003, 170:1171-1179.
10. Honoré B, Vorum H, Pedersen AE, Buus S, Claessen MH: Changes in protein expression in p53 deleted spontaneous thymic lymphomas. *Cell Res* 2004, 14:91-101.
11. Honoré B, Østergaard M, Vorum H: Functional genomics studied by proteomics. *Bioessays* 2004, 26:901-915.
12. Hosaka M, Toda K, Takatsu H, Torii S, Murakami K, Nakayama K: Structure and intracellular localization of mouse ADP-ribosylation factor type 1 to type 4 (*ARF1*-*ARF6*). *J Biochem* 1996, 120(4):813-819.
13. Hemminga BA, Adams-Pearson C, Maurer F, Muller P, Goris J, Merlvede W, Hofsteenge J, Stone SR: alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have a similar amino acid repeating structure. *Biochemistry* 1990, 29:3166-3173.
14. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L: Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. *Clin Exp Metastasis* 2002, 19:319-326.
15. Chutrapatis A, Slayfield R, Kerr ID, Hughes C, Eremin O: Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. *Int J Oncol* 2007, 30:1545-1551.
16. Nakamura Y: Isolation of p53-target genes and their functional analysis. *Cancer Sci* 2004, 95:7-11.
17. Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. *OncoGene* 2005, 24:2899-2908.
18. Shu XK, Li B, Wu LX: The p53 network: p53 and its downstream gene products. *Curr Opin Biotechnol* 2007, 18:10-18.
19. Comer KA, Dennis PA, Armstrong L, Catino JJ, Kastan MB, Kumar CC: Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein. *OncoGene* 1998, 16:1299-1308.
20. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al.: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet* 2000, 25:25-29.